Bristol Myers Squibb Company $BMY Shares Bought by Oak Harvest Investment Services

Oak Harvest Investment Services lifted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 5.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 168,043 shares of the biopharmaceutical company’s stock after buying an additional 8,692 shares during the period. Oak Harvest Investment Services’ holdings in Bristol Myers Squibb were worth $7,779,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in BMY. Vanguard Group Inc. grew its stake in shares of Bristol Myers Squibb by 0.8% in the first quarter. Vanguard Group Inc. now owns 191,403,004 shares of the biopharmaceutical company’s stock worth $11,673,669,000 after purchasing an additional 1,458,488 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Bristol Myers Squibb by 0.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 60,606,905 shares of the biopharmaceutical company’s stock valued at $3,696,415,000 after buying an additional 306,430 shares in the last quarter. Geode Capital Management LLC increased its stake in Bristol Myers Squibb by 1.6% during the 2nd quarter. Geode Capital Management LLC now owns 46,176,690 shares of the biopharmaceutical company’s stock valued at $2,132,976,000 after buying an additional 723,459 shares during the period. Northern Trust Corp raised its position in shares of Bristol Myers Squibb by 5.3% during the 1st quarter. Northern Trust Corp now owns 25,974,504 shares of the biopharmaceutical company’s stock worth $1,584,185,000 after buying an additional 1,316,144 shares in the last quarter. Finally, Wellington Management Group LLP lifted its stake in shares of Bristol Myers Squibb by 297.0% in the 1st quarter. Wellington Management Group LLP now owns 23,728,443 shares of the biopharmaceutical company’s stock worth $1,447,198,000 after acquiring an additional 17,750,938 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the sale, the executive vice president directly owned 167,379 shares of the company’s stock, valued at $7,922,048.07. This represents a 25.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.09% of the company’s stock.

Bristol Myers Squibb Stock Down 0.9%

BMY stock opened at $48.64 on Friday. The company has a 50 day moving average of $45.35 and a two-hundred day moving average of $46.71. The company has a market cap of $99.02 billion, a price-to-earnings ratio of 19.61, a PEG ratio of 2.23 and a beta of 0.33. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.52 by $0.11. The business had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm’s revenue was up 2.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, equities analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd were given a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 5.1%. The ex-dividend date of this dividend was Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio is currently 83.78%.

Analysts Set New Price Targets

BMY has been the topic of several recent analyst reports. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday, October 13th. Daiwa America downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 3rd. Four equities research analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $54.58.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.